组织型纤溶酶原激活剂的发光分析法及其应用

 本文建立了组织型纤溶酶原激活剂(t-PA)活力的发光固相测定方法。用氨基乙基丁基异鲁米诺(ABEI)标记纤维蛋白原(Fg),在一定条件下,t-PA作用于固相(包被ABEI-Fg),产生纤维蛋白的降解产物。测定可溶性降解产物的发光强度,即能计算t-PA活性。该方法的标准曲线范围对t-PA为0.156IU/mL～40IU/mL。灵敏度可达0.156IU/mL。回收率为98.6％(n=27)。批内批间变异系数分别为6.6％及10.3％。该方法曾用于检测细胞培养液中提取t-PA样品及t-PA基因表达时培养液中t-PA的活性。也曾用于检测从组织中纯化t-PA样品及血浆中t-PA活性的测定。文中讨论了该方法与其它方法优缺点的比较。     

t-PA昆虫细胞表达及特性分析

应用RT-PCR技术,从人黑色素瘤Bowes细胞株中扩增出人组织型纤溶酶原激活剂(tissue-typeplasminogenactivator,t-PA)cDNA。序列分析证实,与国外的报道完全一致。将含完整阅读框架的人t-PAcDNA克隆至昆虫细胞表达转移载体pBacPAK8中,获得重组质粒pBac-tPA。应用脂质体共转染法,将pBactPA和线性化杆状病毒BacPAK6DNA共转染Tn-5B-1昆虫细胞。经空斑筛选获得11株重组病毒。经PCR鉴定与生物活性测定,获得一株高效表达t-PA的重组病毒BactPA3。在含胎牛血清的培养基中,t-PA表达活性在感染(MOI≈10)后72h左右达到最高,为3.04×103IU／ml,即相当于1.8×104IU／106细胞;在无血清培养基中,t-PA最高表达水平相差不大,但时间为感染后132h左右。经SDS-PAGE纤维蛋白自显影分析,分子量为68kda左右。与从人黑色素瘤细胞培养液中提纯的天然t-PA相比,其受纤维蛋白原激活的特性、和纤维蛋白的亲和力及在血浆中的失活速率基本相同。表达的t-PA在血液循环中的半衰期为7min。     

t-PA cDNA在CHO细胞中的高效稳定表达

我们曾报道t-PA mRNA非翻译区序列对其表达有明显的抑制作用,在此基础上,通过对5′-UTR及3′-UTR的改造,使t-PA在COS-7细胞中的表达水平提高30倍左右。将t-PA表达质粒用电击法转染中国仓鼠卵巢细胞二氢叶酸还原酶缺陷株(CHO-dhfr),经过混合加压及筛选,在CHO细胞中高效表达了t-PA,表达水平达到5000～6000 IU/10~6细胞/24hr。重组t-PA具有与天然t-PA相同的分子量及酶活性。经过8个月连续传代,表达水平未下降,表明细胞株是稳定的,其主要指标均符合工程细胞株的要求。     

人组织型纤溶酶原激活剂表达调控及高效表达的研究——Ⅱ.t-PA cDNA在CHO细胞中的高效稳定表达

曾报道t-PA mRNA非翻译区序列对其表达有明显的抑制作用,在此基础上,通过对5′-UTR及3′-UTR的改造,使t-PA在COS-7细胞中的表达水平提高30倍左右。将t-PA表达质粒用电击法转染中国仓鼠卵巢细胞二氢叶酸还原酶缺陷株(CHO-dhfr^- ),经过混合加压及筛选,在CHO细胞中高效表达了t-PA,表达水平达到5000～6000IU/10~6细胞·d^-1.重组t-PA具有与天然t-PA相同的分子量及酶活性。经过8个月连续传代,表达水平未下降,表明细胞株是稳定的,其主要指标均符合工程细胞株的要求。     

组织型纤溶酶原激活剂(t-PA)突变体工程细胞株生物学特性分析

t-PA突变体工程细胞株FSGGI48形态与其亲代细胞CHO-dhfr相似呈多角形,类似上皮细胞。在MTX加压至5×10~(-6)mol/L时,少数细胞形态略变瘦长,但仍呈多角形,因此该工程细胞株形态正常。抗体中和抑制试验及纤维蛋白板80℃加热试验显示,FSGGI48细胞表达产物与st-PA的活性均能被抗t-PA抗体所抑制,而胰酶的活性则不被抑制,且二者在80℃加热的纤维蛋白板上均不产生溶解圈,胰酶则产生溶解圈,由此可知,该细胞株表达产物为特异的rt-PA产品。细胞无血清培养上清经FA-PA检测,亚克隆株表达水平为4000IU/10~6细胞/24h。分别测定冻存3个月后复苏和体外传代3个月以上细胞的表达水平,结果显示部分亚克隆细胞株表达水平下降,多数仍为3000-4000IU/10~6细胞/24h,说明细胞株稳定性好。裸鼠试验表明,该工程株活细胞、细胞DNA、纯化的细胞表达产物均无致瘤性。支原体检查结果为阴性。染色体分析显示,FSGGI48细胞与其亲代细胞(CHO-dhfr细胞)染色体数目相同均为20条,但均有不同程度不同类型的畸变。CHO-dhfr细胞畸变率为6%。该工程细胞的畸变率为15%-18%,在允许范围内。结果证明,t-PA突变体细胞株FSGGI48为性能优良的工程细胞株。     

蝮蛇毒PCA对脑梗死大鼠PC活性变化的影响及其机制

目的探讨脑梗死大鼠血浆蛋白C(PC)活性变化与蝮蛇毒蛋白C激活物(PCA)对其的影响及其可能机制。方法将SD雄性大鼠32只,随机分为正常对照组(C组)、脑梗死组(CI组)、阳性对照组(UK组)和实验组(PCA组),每组8只。采用血管内直接线栓闭塞法制备大鼠缺血性脑梗死模型,UK组和PCA组分别静脉注射UK和PCA。实验1h后于颈总动脉取血,以发色底物法检测血浆PC活性;测定APTT值;观察血浆PC活性和凝血功能的变化。24h后处死大鼠,开颅取脑TTC染色且行HE染色。结果 CI组大鼠血浆PC活性明显低于C组(P<0.01),APTT无明显改变(P>0.05);PCA组PC活性较CI组明显升高(P<0.01)。病理切片HE染色显示,CI组神经细胞数明显减少,形态发生改变,形状不规则,细胞固缩、深染;UK组与PCA组注射药物后脑梗死病变区表现近似,与正常对照组比较无明显变化。结论缺血性脑梗死与血浆PC活性显著降低有关;PCA可在一定程度上恢复和提高PC的活性,降低脑梗死发生的风险。     

游泳训练对高血压大鼠血压及血栓前状态分子的影响*

目的: 观察10周游泳训练对自发性高血压大鼠(SHR)血压及血栓前状态分子血管性血友病因子(vWF)、组织型纤溶酶原激活物(t-PA)、纤溶酶原激活物抑制物(PAI-1)的影响。方法: 选取10周龄雄性SHR(18只),随机分为对照组(8只)和训练组(10只),SHR训练组进行5次/周,每次60 min,共持续10周的无负重游泳训练,期间每2周测定大鼠血压。10周训练后,分别测定两组SHR血小板聚集率、血浆vWF、t-PA和PAI-1。结果: 与对照组相比,训练组SHR经4周游泳训练后,血压显著下降(P＜0.05),经10周游泳训练后,血压、血小板聚集率、血浆vWF水平、PAI-1活性显著降低(P＜0.01),血浆t-PA活性显著提高(P＜0.01)。结论: 适宜游泳训练能有效平抑(或改善)SHR的血压,坚持4周训练即可产生显著的作用,还可明显改善SHR血栓前状态,预防高血压血栓性并发症。     

t-PA在哺乳动物细胞中的表达调控及高效表达

人组织型纤溶酶原激活剂(t-PA)对纤维蛋白有较强的亲和力,可选择性溶解血栓而不引起全身出血倾向,所以是一种较理想的溶血栓药物。美国的重组t-PA已通过FDA批准,应用于临床,每年销售达数亿美元。国内上医,北大,南大及我所先后开展了t-PA在CHO细胞中的表达的研究,经多年努力表达水平约1～2μg(200～400IU)/10~6细胞/24小时,但该水平离中试生产尚有差距。     

前肽缺失体vWF改善FVIII基因断裂转移 细胞的重链和活性分泌

通过转von Willebrand因子(vWF)的前肽缺失突变体(vWF-ΔPro)基因,探讨了vWF-ΔPro对双载体转凝血VⅢ因子(FVⅢ)基因的影响。将vWF-ΔPro基因和B-区缺失型FVⅢ(BDD-FVⅢ)的重、轻链基因共转染HEK293细胞48 h后,ELISA检测重链的分泌量为(142±29)ng/ml,明显高于未转vWF-ΔPro基因细胞(87±15)ng/ml;未转vWF-ΔPro基因时单独转重链基因的重链分泌水平很低,vWF-ΔPro存在时重链分泌量明显提高,但不如共转基因时的重链分泌,提示轻链可反式促进重链分泌;单独转轻链或与重链共转基因时轻链分泌水平均较高,且不受vWF-ΔPro影响;Coatest法检测分泌的凝血活性显示,转vWF-ΔPro基因可使细胞分泌的凝血活性明显高于未转vWF-ΔPro基因细胞(0.80±0.15 IU/ml vs 0.41±0.08 IU/ml)。另外,转vWF-ΔPro基因条件下,合并培养转重链和转轻链基因细胞的培养上清中,也检测到FVIII凝血活性(0.23±0.09IU/ml),提示vWF-ΔPro有助于分泌的重、轻链形成功能性异源二聚体。表明转vWF-ΔPro基因可促进双链转FVⅢ基因,为进一步动物体内实验奠定了基础。     

抗人PAI—1单克隆抗体制备,鉴定和应用

以重组PAI-(rPAI-1)为抗原,通过杂交瘤技术获得6株阳性杂交瘤细胞(AP1、AP2、AP3、AP4、AP5和AP6),并用SPA亲和层析纯化了抗PAI-1单克隆抗体(McAb)。所有McAb均能识别rPAI和天然PAI-1,腹水滴度均为10~6以上。6种McAb对PAI-1亲和常数在3.45×10~7—1.05×10~9mol/L之间。AP2、AP3 McAb能完全抑制PAI-1活性,AP4、AP和AP6只能部分抑制PAI-1活性,AP1则不抑制PAI-1活性。6种McAb中只有AP1、AP4和AP5能识别PAI-1/t-PA复合物。利用AP1、AP3、和AP4 McAb制备免疫亲和柱一步纯化HepG_2细胞分泌的PAI-1,纯度大于98％,回收率92％,纯化倍数51倍。利用抗PAI-1 McAb建立了夹心法ELISA,测定了人血浆PAI-1水平,正常人血浆PAI-1平均含量(±D)为24.7±7.75ng/ml。     

Radioimmunoassay of apolipoprotein A-I of rat serum.

A double antibody radioimmunoassay technique was developed for quantification of apolipoprotein A-I, the major apoprotein of rat high density lipoprotein. Apo A-I was labeled with 125I by the chloramine-T method. 125I-labeled apo A-I had the same electrophoretic mobility as unlabeled apo A-I and more than 80% of the 125I was precipitated by rabbit anti apo A-I antibodies. The assay is sensitive at the level of 0.5-5 ng, and has intraassay and interassay coefficients of variation of 4.5 and 6.5% respectively. The specificity of the assay was established by competitive displacement of 125I-labeled apo A-I from its antibody by apo A-I and lipoproteins containing apo A-I, but not by rat albumin and other apoproteins. Immunoreactivity of high density lipoprotein and serum was only about 35% of that of their delipidated forms when Veronal buffer was used as a diluent. Inclusion of 5 mM sodium decyl sulfate in the incubation mixture brought out reactivity equivalent to that found after delipidation. Completeness of the reaction was verified by comparison with the amount of apo A-I in chromatographic fractions of the total apoprotein of high density lipoprotein. Content (weight %, mean values +/- S.D.) of immunoassayable apo A-I was: 62.3 +/- 5.9 in high density lipoprotein; 1.7 +/- 0.3 in low density lipoprotein; 0.09 +/- 0.03 in very low density lipoprotein and 25.0 +/- 5.0 in lymp chylomicrons. Concentration in whole serum was 51.4 +/- 8.9 mg/dl and 33.6 +/- 4.1 mg/dl for female and male rats, respectively (p less than 0.002), equivalent to the sex difference in concentration of high density lipoprotein. 95% of the apo A-I in serum was in high density lipoprotein, 5% in proteins of d greater than 1.21 g/ml and less than 1% in lipoproteins of d less than 1.063 g/ml.     

抗—HBs国际单位RIA一点法定量测定与计算方法的探讨

在Radio-immuno Assay(RIA)试验测抗－HBs国际单位的简易定量与计算中,采用RIA一点法测定,以分析表达式mIU/ml＝SC（mIU/ml)[exp(0.69315S-NC/SC-NC-1]进行结果计算。此式可以常用对数式表示为mIU/ml=SC(mIU/ml)[lg^-1(0.30103S-NC/SC-NC-1],当（S－NC）在0．3－1．1界线内时,其计算结果的相对误差小于6％,是目前误差最小的简易计算方法。同时还推算求出Holliger公式的阳性对照的最适含量为124．26mIU／ml,Richardson公式的阳性对照为125mIU/ml,中国药品生物制品检定所公式的阳性对照为92．5mIU/ml。     

Competitive protein binding assay for activin A/EDF using follistatin determination of activin levels in human plasma.

A sensitive and specific protein binding assay for activin A/EDF (activin) was developed using follistatin as a binding protein and [125I] labelled activin as a tracer. As 50% acetonitrile (CH3CN) separated free and follistatin-bound activin, plasma pretreated with an equal volume of CH3CN was used as the assay sample and B/F separation was also done with 50% CH3CN. The recovery of the assay was 85.0% and its sensitivity was 0.5 ng/ml. Crossreactivity with inhibin A was 1.8%. The mean plasma level of follistatin-free activin in normal subjects was 1.3 +/- 0.7%. (M +/- SD) ng/ml. Plasma free activin levels were generally elevated in patients with chronic renal failure or hematological diseases associated with anemia.     

Evaluation of a new radioimmunological assay for the determination of the B subunit of creatine kinase enzyme

We used a new radioimmunological (RIA) kit for the assay of B subunit of creatine kinase enzyme (CK). This RIA system uses a specific antisera against the B subunit as ligant, human CK-BB labelled with 125I as tracer, and purified human CK-BB isoenzyme as standard. The mean (+/- SD) sensitivity obtained was 0.25 +/- 0.16 ng/tube and the between assay variability was about 9-10%. Serum levels of 113 normal subjects was not normally distributed. The 95% of values was found below 5 ng/ml. This new RIA is usefull in clinical practice when serum levels of CK-BB isoenzyme must be determined. This method is quickly and it is characterized by a good degree of precision, but the CK-MB isoenzyme cross-reacts for about 40% in this RIA system. Therefore, for the clinical diagnosis by means of this RIA it is necessary to rule out the concomitant elevations of serum CK-MB values.     

Radioimmunoassay for 11-deoxycortisol using iodine-labeled tracer.

A simple and sensitive radioimmunoassay for 11-deoxycortisol was developed. The antiserum produced in rabbits by immunizing with a complex of 11-deoxycortisol-3-oxime and bovine serum albumin (BSA) has little cross-reactivity with other endogenous steroids. The immunoassay procedure requires only one-step ethanol denaturation of binding proteins in plasma and extraction by an organic solvent can be omitted. Furthermore, use of 125I-labeled tracer significantly simplify the counting procedure. The method is sensitive enough to detect 1 microng/100 ml of 11-deoxycortisol. Plasma 11-deoxycortisol levels measured by this method after the administration of a single dose of metyrapone ranged from 5.0 to 19.2 microng/100 ml, whereas they were 0 to 4.0 microng/100 ml in hypopituitary patients. It is concluded that this simple method is useful for the routine assay of plasma 11-deoxycortisol as a parameter of the metyrapone tests.     

A radioreceptor assay for insulin: direct measurement of dog pancreatic vein serum insulin.

A simple radioreceptor assay for insulin rat liver membranes as receptor sites, with sufficient specificity precision, and sensitivity to detect 10 ng or 276 muU/ml of serum insulin, has been developed. In the presence of standard porcine insulin at the concentration of 1.0 ng/tube, approximately 8% of 125I-porcine insulin was bound to the plasma membranes and ninety-five per cent of this binding was inhibited by 1.0 microgram of standard insulin per tube. Four animal insulins inhibited the binding of 125I-insulin while ACTH, glucagon, human growth hormone, and oxytocin were inert. Insulin values in dog pancreatic vein sera obtained during and after glucose loading and measured by the present radioreceptor assay agreed well with immunoreactive insulin. The ratio of IRI to the measurement by radioreceptor assay was 1.09 +/- 0.18 for the same sera.     

Transferrin in fetal sheep cerebrospinal fluid and plasma during gestation

1. Transferrin concentrations in fetal sheep CSF and plasma have been estimated between 31 and 125 days gestation and in the adult, using a radial immunodiffusion assay. 2. The plasma concentration was lowest (183 +/- 35 mg/100 ml) in the earliest fetuses examined (31 days). It increased to over 350 mg/100 ml by 35 days; thereafter it was around the adult value (580 mg/100 ml). 3. In CSF the transferrin concentration increased from 43 +/- 10 mg/100 ml at 31 days to a maximum of 163 +/- 14 mg/100 ml at 40 days gestation after which it decreased considerably to 6.1 +/- 0.7 mg/100 ml at 125 days and was even lower in the adult (1.1 +/- 0.2 mg/100 ml). 4. CSF: plasma ratios for transferrin especially when compared with those of other plasma proteins, are not compatible with passive leakage of protein from blood to CSF in the developing brain. The results may be explained by specific transfer of proteins into CSF but synthesis by the choroid plexus or brain has not been excluded.     

A stimulatory effect of the fluid from preimplantation rabbit blastocysts upon luteinization of monkey granulosa cell cultures.

Blastocyst fluid was aspirated from Day 6 1/2--7 rabbit blastocysts and was added to cultures of granulosa cells obtained from preovulatory follicles of untreated rhesus monkeys or from follicles of monkeys or from follicles of monkeys treated with PMSG. The stimulation of progesterone secretion was measured and equated with that produced by hCG. The hCG-like activity was also measured in a radioreceptor assay using 125I-labelled hCG and porcine granulosa cells. In 8 out of 10 experiments with cultured cells from untreated monkeys, addition of 20% blastocyst fluid from Days 6--9 of culture stimulated progesterone secretion by 2- to 6-fold. Similar findings were obtained in 5 experiments with cultures from PMSG-treated monkeys except that the blastocyst fluid was added from Days 0 to 6 of culture. The granulosa cells in such cultures underwent morphological luteinization. Compared to a standard of purified hCG the blastocyst fluid contained about 0.76--2.5 ng hCG-like activity/ml which was non-dialysable. The radioreceptor assay indicated the presence of 0.5--2.5 ng hCG-like material/ml.     

Radioimmunoassay of arginine-rich apolipoprotein of rat serum.

A double-antibody radioimmunoassay was developed for quantification of rat arginine-rich apolipoprotein in sodium decyl sulfate. Arginine-rich protein, labeled with 125I by the chloramine-T method, had the same chromatographic characteristics on Sephadex G-200 as unlabeled arginine-rich protein and up to 70% of 125I-labeled arginine-rich protein was precipitated by antisera to arginine-rich protein in rabbits. The assay is sensitive at the level of 1-10 ng and has intraassay and interassay coefficients of variation of 5.4 and 6.8%, respectively. The specificity of the assay was established by competitive displacement of 125I-labeled arginine-rich protein from its antiserum by arginine-rich protein and lipoproteins containing this protein, but not by rat albumin or other purified apolipoproteins. Immunoreactivity of rat serum and lipoproteins was complete as demonstrated by comparison with their delipidated form. The accuracy of the immunoassay was further substantiated by comparison with the amount of arginine-rich protein in chromatographic fractions of total apoprotein of very low and high density lipoproteins, and by recovery experiments in ultracentrifugally separated fractions of serum. In contrast to an immunoassay reported previously for rat apo A-I, sodium decyl sulfate was not required for complete immunoreactivity of serum and lipoproteins. The inclusion of sodium decyl sulfate (9 mM final concentration) was necessary, however, for stability of labeled and unlabeled preparations of arginine-rich protein. Content (weight %, means values +/- S.D.), of immunoassayable arginine-rich protein in isolated lipoproteins was 15 +/- 1.5% in very density lipoproteins; 6.8% in low density lipoproteins (1.02 less than d less than 1.04 g/m); 7.1 +/- 0.3% in high density lipoproteins; and 4.8 +/- 0.5% in lymph chylomicrons. Concentration in whole serum was 18.1 +/- 1.4 and 20.4 +/- 2.3 mg/dl for male and female rats, respectively. Only about 55% of arginine-rich protein was recovered in the major lipoprotein classes and about 40% was in "lipoprotein-free" serum (d greater than 1.25 g/ml). Among the lipoproteins, the high density lipoprotein fraction contained twice the amount of arginine-rich protein recovered in very low or low density lipoproteins (26.6 vs. 13.5 and 13.4%, respectively). The significance of the large amount of arginine-rich protein in the 1.25 g/ml infranatant fraction is not apparent. Although repetitive centrifugation did not alter the amount recovered in this fraction, the possibility of an artifact induced by centrifugation and high salt concentration cannot be excluded.     

Development of a non-extracted ''two-site'' immunoradiometric assay for corticotropin utilizing extreme amino- and carboxy-terminally directed antibodies.

The development of a 'two-site' immunoradiometric assay (i.r.m.a.) for the direct estimation of human corticotropin-(1-39)-peptide in plasma is described. The assay is based on the simultaneous addition of 125I-labelled sheep anti-(N-terminal corticotropin) IgG (immunoglobulin G) antibodies and rabbit anti-(C-terminal corticotropin) antiserum to standards and unknowns (0.5 ml) followed by 18h incubation. The use of solid-phase reagents was avoided in order to minimize non-specific effects and the time required for reactants to reach equilibrium. Instead, the separation of corticotropin-bound from free labelled antibody is achieved by the addition of sheep anti-(rabbit IgG) antiserum, which precipitates bound labelled antibody by complex-formation with rabbit anti-corticotropin antibodies, which are also hormone-bound. Several 125I-labelled sheep anti-(N-terminal corticotropin) IgG preparations were assessed in the i.r.m.a. Although each was derived from antisera raised to a thyroglobulin conjugate of synthetic corticotropin-(1-24)-peptide (Synacthen), purification of immunoglobulins before iodination by selective immunoadsorption resulted in preparations with distinct specificities which demonstrated marked differences in binding to intact human corticotropin-(1-39)-peptide. These preparations are compared in combination with two rabbit anti-(C-terminal corticotropin) antisera. A 'two-site' assay based on the use of 125I-labelled sheep anti-[ corticotropin-(2-16)-peptide] IgG and rabbit anti-[corticotropin-(34-39)-peptide] antiserum was optimized, since steric inhibition of antibody binding was avoided with this combination and because the measurement of only intact human corticotropin-(1-39)-peptide and not fragments was assured by the use of terminal antibodies. This i.r.m.a. is characterized by rapid equilibration of reactants, a wide 'operating range' (the precision of dose estimates was less than 4% over the range 30-2200 pg/ml) and high sensitivity [8 pg of corticotropin/ml (95% confidence interval 3.7-12.0) (4 pg minimal detectable mass) can be detected directly in plasma].